Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson cOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%)
Form 8-K EX-99.2 Segment Sales Schedule
Latest, FY2024
-82.4%
Period ended Dec 29, 2024
Change on a year earlier
-33.6 pts
-48.8% in FY2023
History
3 years
Since FY2022
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 29, 2024 | -82.4% | -33.6 pts | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
| FY2023 | Dec 31, 2023 | -48.8% | -40.2 pts | Form 8-K (a2023q4exhibit991.htm, filed 2024-01-23) ↗ |
| FY2022 | Jan 1, 2023 | -8.6% | – | Form 8-K (a2022q4exhibit991.htm, filed 2023-01-24) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — Worldwide reported growth YoY (%) (%), annual FY2022–FY2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_covid19_rep_yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.